CYP2J2 and neoplasm: An iTRAQ-based proteomics analyses of the changes in proteome of the MDA-MB-231 and MCF-7 cells upon 12(13)-EpOME treatment screened out PLEC as another key player in EpOME-mediated tumor-promoting effect because it was significantly upregulated in both cells upon 12(13)-EpOME treatment (Fig. 6E,, F), which was further supported by its expression was upregulated by EpOME administration and CYP2J2 overexpression (Fig. 6G, Supplementary Fig. S6C), and its cancer-driven role in EpOME-mediated TNBC development (Fig. 6I–V).